Search results for " vaccine"

showing 10 items of 680 documents

Does the Compliance to Intravesical BCG Differ between Common Clinical Practice and International Multicentric Trials?

2015

<b><i>Introduction:</i></b> The aim of this study was to analyze the reasons for intravesical BCG interruption in clinical practice. BCG for at least one year is advocated as the best regimen to treat high-risk non-muscle invasive bladder cancer (NMIBC). However, almost 50% of patients don't complete it. Toxicity accounts for 10% of dropouts in international trials. <b><i>Materials and Methods:</i></b> Patients with T1HG NMIBC undergoing 1-year BCG were enrolled in this study. BCG was administered for one year. Toxicity and causes of treatment interruption were recorded. <b><i>Results:</i></b> A total of 411 patients we…

AdultMalemedicine.medical_specialtyUrologyInternational CooperationAntineoplastic AgentsSettore MED/24 - UrologiaMedication AdherenceSocial lifeCohort StudiesRecurrenceInternal medicinemedicineHumansAgedBladder cancerbusiness.industryMiddle Agedmedicine.diseaseSurgeryClinical PracticeRegimenAdministration IntravesicalTreatment OutcomeUrinary Bladder NeoplasmsTreatment interruptionToxicityBCG VaccineDisease ProgressionIntravesical bcgPatient ComplianceFemalenon muscle invasive bladder cancer Bacillus Calmette Guèrin intravesical instillation immunotherapy compliance toxicityNeoplasm Recurrence LocalbusinessCohort studyUrologia internationalis
researchProduct

Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared wit…

2011

BACKGROUND: The human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine is immunogenic, has a clinically acceptable safety profile, and prevents incident and persistent HPV-16/18 infection and cervical precancerous lesions. This study (NCT00552279) evaluated the vaccine when administered according to an alternative dosing schedule (0-1-12 months) compared with the standard dosing schedule (0-1-6 months). METHODS: The study was of randomized open design and was conducted at multiple centers in Europe. Healthy women aged 15 to 25 years were randomized (1:1) to receive HPV-16/18 vaccine according to the standard schedule at months 0, 1, and 6 (n = 401) or an alternative schedule at months 0, …

AdultMicrobiology (medical)medicine.medical_specialtyScheduleAdolescentImmunization SecondaryEnzyme-Linked Immunosorbent AssayAntibodies Virallaw.inventionYoung AdultAdjuvants ImmunologicRandomized controlled triallawInternal medicinemedicineHumansPapillomavirus VaccinesDosingHuman papillomavirusYoung adultbusiness.industryImmunogenicityhuman papillomavirus human papillomavirus vaccines adolescent immunology alternative dosing scheduleVaccinationvirus diseasesSettore MED/40 - Ginecologia E Ostetriciafemale genital diseases and pregnancy complicationsEuropeSafety profileInfectious DiseasesImmunizationPediatrics Perinatology and Child HealthImmunologyFemalebusiness
researchProduct

Knowledge and attitudes of parents after the implementation of mandatory vaccination in kindergartens of Palermo, Italy.

2020

Background and aim of the work: Even though vaccination is easy to access in Europe, it has been facing several outbreaks caused by vaccine preventable diseases. Trying to balance the right to health of the community with individual self-determination, in Italy was mandate vaccination for ten vaccine preventable diseases in 2017. The project “Sportello Vaccinale” provided a counseling service to parents in kindergarten of Palermo. The main objective of the study was to investigate knowledge and compliance on vaccination by children’s parents after the implementation of mandatory vaccination. Methods: A cross sectional study was conducted among parents accessing to the “Sportello Vaccinale” …

AdultParentsHealth Knowledge Attitudes PracticeVaccinationMandatory ProgramsAccessibilityHealth Literacymandatory vaccinationCross-Sectional StudiesItalyChild PreschoolHumansOriginal ArticleMMRV vaccineSelf ReportSafetyparent ageSicilyhexavalent vaccinevaccine adherenceHealth Belief ModelActa bio-medica : Atenei Parmensis
researchProduct

Whooping cough, twenty years from acellular vaccines introduction

2015

Clinical pertussis resulting from infection with B. pertussis is a significant medical and public health problem, despite the huge success of vaccination that has greatly reduced its incidence. The whole cell vaccine had an undeniable success over the last 50 years, but its acceptance was strongly inhibited by fear, only partially justified, of severe side effects, but also, in the Western world, by the difficulty to enter in combination with other vaccines: today multi-vaccine formulations are essential to maintain a high vaccination coverage. The advent of acellular vaccines was greeted with enthusiasm by the public health world: in the Nineties, several controlled vaccine trials were car…

AdultPertussis VaccineAcellular vaccinesSecondaryVaccinesSettore MED/07 - Microbiologia E Microbiologia ClinicaTime FactorsAdolescentWhooping CoughMedicine (all)VaccinationImmunization SecondaryVaccine trialInfantVaccines AcellularImmunoprotectionPertussiPertussisAcellularItalyHumansAcellular vaccines; Immunoprotection; Pertussis; Vaccine trials; Adolescent; Adult; Humans; Immunization Secondary; Infant; Italy; Pertussis Vaccine; Time Factors; Vaccination; Vaccines Acellular; Whooping CoughImmunizationVaccine trialsAcellular vaccine
researchProduct

The 2014 lifetime immunization schedule approved by the Italian scientific societies. Italian Society of Hygiene, Preventive Medicine, and Public Hea…

2014

AdultSecondaryAdolescentAdolescent; Adult; Age Factors; Aged; Child; Child Preschool; Humans; Immunization Secondary; Infant; Infant Newborn; Italy; Middle Aged; Societies Medical; Vaccination; Vaccines; Young Adult; Immunization ScheduleImmunization SecondaryYoung AdultMedicalHumansAge FactorPreschoolChildImmunization ScheduleSocieties MedicalAgedVaccinesVaccinationAge FactorsInfant NewbornInfantMiddle AgedNewbornSettore MED/38ItalyChild PreschoolImmunizationSocietiesVaccineHuman
researchProduct

Pneumococcus infections: Is the burden still as heavy?

2012

EA MERS CT3 Enjeu 3; International audience; The death rate of invasive pneumococcal infections decreased by 100 fold in one century. This tremendous improvement was due mainly to antibiotic use and multiple attempts at antipneumococcal vaccinations; thus, this was true only for developed countries. However, in France, the incidence has increased, over the last 10 years, in all age classes except for children vaccinated by the heptavalent pneumococcal conjugate vaccine. The incidence of these infections remains high, when associated to some risk factors such as HIV infection, malignant blood diseases, solid cancers, bronchial diseases, or alcohol abuse. The pneumococcal vaccine should be pr…

AdultSerotypeHeptavalent Pneumococcal Conjugate Vaccine[SDV]Life Sciences [q-bio]Immunization SecondaryAlcohol abuseGlobal HealthPneumococcal InfectionsPneumococcal Vaccines03 medical and health sciences0302 clinical medicineRisk FactorsHeptavalent Pneumococcal Conjugate Vaccine[SDV.BV]Life Sciences [q-bio]/Vegetal BiologyHumansMedicineserotype030212 general & internal medicineSerotypingChildinfection invasive à pneumocoque0303 health sciences030306 microbiologybusiness.industrypneumococcal invasive infectionDeveloped CountriesIncidenceMortality rateIncidence (epidemiology)VaccinationAge Factorssérotypemedicine.disease3. Good healthVaccinationPneumococcal infectionsStreptococcus pneumoniaeInfectious DiseasesPneumococcal vaccine[SDE]Environmental SciencesImmunologyDisease SusceptibilityFrancebusinessMédecine et Maladies Infectieuses
researchProduct

Experts’ Opinion for Improving Pertussis Vaccination Rates in Adolescents and Adults: A Call to Action

2022

This article highlights the importance of diphtheria-tetanus-acellular pertussis (with reduced antigen content, dTap) vaccination in preventing pertussis, a respiratory infection that is still widespread and easily transmitted. In particular, it highlights the need to receive a booster vaccination throughout life to maintain high antibody levels, which decrease through time. This document collects the opinions that emerged from the comparison between major Italian experts in the field of vaccination. This working group was created to promote a “call to action”, aimed at raising awareness among all institutions, public health authorities, and health workers involved in the vaccination proces…

AdultTetanuspertussis vaccineAdolescentWhooping CoughHealth Toxicology and MutagenesisVaccinationpertussis vaccine in pregnancy.Public Health Environmental and Occupational Healthpertussis booster for adultDiphtheriapertussis immunity durationDiphtheria-Tetanus-acellular Pertussis VaccinesAntibodies Bacterialpertussis immunizationdTap vaccinePregnancypertussiHumansFemaleDiphtheria-Tetanus-Pertussis VaccineInternational Journal of Environmental Research and Public Health
researchProduct

Anti-diphtheria antibody seroprotection rates are similar 10 years after vaccination with dTpa or DTPa using a mathematical model

2003

The reduced antigen content diphtheria, tetanus and pertussis (dTpa) vaccine (Boostrixtrade mark) has been shown to induce a strong booster response to all the vaccine components in 4-6 year olds. However, anti-diphtheria antibody levels were observed to be lower when compared to the "full strength" paediatric DTPa vaccine. To assess the impact of this difference on long-term protection, a mathematical model was developed to predict diphtheria antibody decay over time. The model was based on a linear decrease in log-transformed antibody concentrations after the first year post-vaccination. When applied to data collected 3.5 years after vaccination of 4-6 year olds with either DTPa or dTpa, …

AdultTime Factorsanimal diseasesImmunization SecondaryModels Biologicalcomplex mixturesCohort StudiesAntigenmedicineHumansChildDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleRandomized Controlled Trials as TopicBooster (rocketry)General VeterinaryGeneral Immunology and MicrobiologybiologyTetanusbusiness.industryDiphtheriaVaccinationPublic Health Environmental and Occupational HealthDiphtheriarespiratory systemmedicine.diseaseAntibodies BacterialVaccinationInfectious DiseasesImmunizationChild PreschoolImmunologycardiovascular systembiology.proteinMolecular MedicineAntibodybusinessDiphtheria antibodycirculatory and respiratory physiologyVaccine
researchProduct

Hepatitis B vaccination of relatives of hepatitis B virus DNA positive carriers: an experience with plasma-derived vaccine.

1989

We assessed in a western population the efficacy of a plasma-derived hepatitis B vaccine in relatives of highly infectious hepatitis B virus (HBV) carriers. A consecutive group of 103 HbsAg, anti-HBs and anti-HBc negative household relatives of 45 HBV-DNA positive chronic carriers received a 5 micrograms dose of plasma-derived vaccine at 0, 1, 2 and 12 months. Protective levels of immunity developed in 101 subjects (97.8%) 3 months after boosting. Low responders to the vaccine were mostly found among parents and spouses of carriers, whilst offspring and siblings were usually high responders. The main discriminant in predicting a good response was age below 12 years. Hyporesponsiveness did n…

AdultViral Hepatitis VaccinesHBsAgHepatitis B vaccineEpidemiologyPopulationmedicine.disease_causeImmune systemImmunityRisk FactorsMedicineHumansHepatitis B VaccinesHepatitis B AntibodieseducationHepatitis B viruseducation.field_of_studyHepatitis B Surface Antigensbusiness.industryInfant Newbornvirus diseasesInfantHepatitis Bmedicine.diseaseHepatitis BVirologyHepatitis B Core Antigensdigestive system diseasesVaccinationImmunologyCarrier StatebusinessDNA ProbesEuropean journal of epidemiology
researchProduct

Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 y…

2009

This observer-blind study compared the prophylactic human papillomavirus (HPV) vaccines, Cervarix (GlaxoSmithKline) and Gardasil (Merck), by assessing immunogenicity and safety through one month after completion of the three-dose vaccination course. Women (n = 1106) were stratified by age (18-26, 27-35, 36-45 years) and randomized (1:1) to receive Cervarix (Months 0, 1, 6) or Gardasil (Months 0, 2, 6). At Month 7 after first vaccination, all women in the according-to-protocol cohort who were seronegative/DNA negative before vaccination for the HPV type analyzed had seroconverted for HPV-16 and HPV-18 serum neutralizing antibodies, as measured by pseudovirion-based neutralization assay (PBNA…

Adultmedicine.medical_specialtyAdolescentImmunologyAntibodies ViralCancer VaccinesSerologyYoung AdultHuman Papillomavirus Recombinant Vaccine Quadrivalent Types 6 11 16 18Neutralization TestsInternal medicinemedicineHumansPapillomavirus VaccinesGeneral Pharmacology Toxicology and PharmaceuticsNeutralizing antibodyPapillomaviridaeCervical cancerbiologybusiness.industryImmunogenicityGardasilPapillomavirus InfectionsMiddle Agedmedicine.diseaseAntibodies NeutralizingVaccinationImmunologyCohortbiology.proteinFemaleCervarixbusinessmedicine.drugHuman Vaccines
researchProduct